Search for Clinical Trial Results

Sponsored By

Lymphoma, Extranodal NK-T-Cell - 25 Studies Found

Status Study
Recruiting Study Name: Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL
Condition: Lymphoma, Extranodal NK-T-Cell
Date: 2014-03-02
Interventions:
  • Drug: GELOX gemcitabine ᦂ
Not yet recruiting Study Name: 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma
Condition: Lymphoma, Extranodal NK-T-Cell
Date: 2017-02-09
Interventions: Device: 18F-FDG PET/ CT 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients
Not yet recruiting Study Name: Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma
Condition: Lymphoma, Extranodal NK-T-Cell
Date: 2017-02-09
Interventions: Device: 18F-FDG PET/CT 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients
Terminated Study Name: P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens
Condition: Lymphoma, Extranodal NK-T-Cell
Date: 2015-08-24
Interventions:
  • Drug: gemcitabine gemcitabine

Recruiting Study Name: GLIDE Regiment Followed by ASCT for Aggressive NK/T Cell Lymphoma
Condition: Lymphoma, Extranodal NK-T-Cell
Date: 2017-05-02
Interventions: Drug: GLIDE The dose and schedule of GLIDE chemotherapy was as follows: gemcitabine 800 mg/m 2 days 1, 8
Recruiting Study Name: Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage
Condition: Lymphoma, Extranodal NK-T-Cell
Date: 2015-02-04
Interventions:
  • Drug: Gemcitabine gemcitabine

Recruiting Study Name: MESA Treatment for NK/T Cell Lymphoma
Condition: Lymphoma, Extranodal NK-T-Cell
Date: 2013-08-16
Interventions:
  • Drug: MESA chemotherapy Methot
Not yet recruiting Study Name: Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation
Condition:
  • Lymphoma, Extranodal NK-T-Cell
  • EBV

Date: 2016-08-20
Interventions:
  • Drug: Chidamide BIW Chidamide

Recruiting Study Name: Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
Condition:
  • Lymphoma, Extranodal NK-T-Cell
  • EBV

Date: 2013-09-13
Interventions: Biological: CMD-003 Autologous EBV-specific T-cells
Active, not recruiting Study Name: Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
Condition:
  • Lymphoma, T-Cell
  • Lymphoma, Extranodal NK-T-Cell

Date: 2003-09-17
Interventions:
  • Biological: Alemtuzumab (Campath)

Next >>>